Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Encephalitis Treatment Market

Encephalitis Treatment Market Share

Report ID: GMI5756
Published Date: May 2023
Report Format: PDF

Download Free Sample

Encephalitis Treatment Market Share

The key players in encephalitis treatment market are :

Pfizer Inc.
Merck & Co., Inc.
Allergan
GlaxoSmithKline plc
Abbott Laboratories
FHoffmann-La Roche Ltd.
Sanofi
Teva Pharmaceutical Industries Ltd.
Basilea Pharmaceutical Ltd.
Melinta Therapeutics LLC.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for encephalitis treatment was worth USD 20.6 billion in 2022 and is set to exhibit around 4.7% CAGR from 2023 to 2032 attributed to the growing incidence of encephalitis and the rising government initiatives and healthcare expenditure.

The antiviral agent segment is expected to grow exponentially through 2032 owing to its increasing use for treating primary encephalitis due to its widespread availability and cost-effectiveness.

The North America encephalitis treatment market generated the highest revenue in 2022 and is poised to depict robust growth through 2032 on account of massive investments in R&D for developing new drugs for treating encephalitis coupled with the presence of key players.

Pfizer Inc., Merck & Co., Inc., Allergan, GlaxoSmithKline plc, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Sanofi, Teva Pharmaceutical Industries Ltd., Basilea Pharmaceutical Ltd., and Melinta Therapeutics LLC are the major players in the global market.